
Is Amneal Pharmaceuticals (AMRX) stock Halal?
Verdict for Amneal Pharmaceuticals (AMRX): not Shariah compliant (FAIL). Screened October 2026 under AAOIFI Shariah Standard No. 21. Business activity: pass. Non-permissible income: pass. Interest-bearing investments: pass. Interest-bearing debt: fail. Preference shares: pass. Dividend purification factor: not applicable. Next review: November 2026.
Amneal Pharmaceuticals is a renowned entity in the pharmaceutical industry, known for its focus on the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The company's chief purpose is to deliver high-quality, cost-effective medication alternatives that contribute to the affordability and accessibility of healthcare. Amneal's extensive portfolio spans a wide range of therapeutics, including prescription generic drugs across various forms and delivery systems. For Muslim investors, though, the most pressing question is simpler: is Amneal Pharmaceuticals a Halal investment?
Is Amneal Pharmaceuticals Shariah compliant?
No. In the October 2026 screening Amneal Pharmaceuticals (AMRX) does not pass AAOIFI screening: it fails the interest-bearing debt screen. Medicines and medical devices are permissible, and healthcare companies like Amneal Pharmaceuticals usually clear the activity screen comfortably. What AAOIFI Shariah Standard No. 21 watches is the financing behind the pipeline: drug development is expensive, and the 30% interest bearing debt cap decides the verdict more often than the science does.
Does Amneal Pharmaceuticals pass the business activity test?
The activity screen is only part of the picture this month: Amneal Pharmaceuticals currently fails the interest-bearing debt screen, so the overall verdict is not compliant regardless of the business itself. Treating illness is permissible work; the scrutiny belongs to the financing behind it.
Is Amneal Pharmaceuticals' income Halal?
Yes, within AAOIFI's tolerance. Amneal Pharmaceuticals' income from non-permissible sources stays below 5% of revenue in the October 2026 screening.
Does Amneal Pharmaceuticals meet AAOIFI's debt and investment ratio requirements?
Not in full. Interest bearing debt currently exceeds the 30% cap, measured against a market capitalisation of $7.01B (market data as of 1 October 2026), while the other ratio stays within it. One breach is enough to fail the screening; the ratios are reassessed monthly under our Shariah Supervisory Board.
Why do other halal screeners show a different verdict for Amneal Pharmaceuticals?
Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.
Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.
New to the screening method? Read What is Halal Investing? A Guide to Halal Stocks and Islamic Finance









